FGF19 and atrial fibrillation: Although the damage caused by GM‐derived BAs has been uncovered in several diseases, evidence for the role of a GM–BA–FGF19 axis in AF progression is still lacking, hampering the progress of future GM intervention strategies to target cardiac arrhythmias.